Integrating real‐world data in cost‐effectiveness analysis of universal HLA‐B*15:02 screening in Malaysia.

Aims: Despite the availability of newer antiseizure medications, carbamazepine (CBZ) remains the gold standard. However, patients of Asian ancestry are susceptible to CBZ‐related severe cutaneous adverse reactions. Universal HLA‐B*15:02 screening is a promising intervention to address this. With the increasing recognition of integrating real‐world evidence in economic evaluations, the cost‐effectiveness of universal HLA‐B*15:02 screening was assessed using available real‐world data in Malaysia. Methods: A hybrid model of a decision tree and Markov model was developed to evaluate 3 strategies for treating newly diagnosed epilepsy among adults: (i) CBZ initiation without HLA‐B*15:02 screening (current practice); (ii) universal HLA‐B*15:02 screening prior to CBZ initiation; and (iii) alternative prescribing without HLA‐B*15:02 screening. The model was populated with real‐world inputs derived from the Malaysian population. From a societal perspective, base‐case analysis and sensitivity analyses estimated the costs and outcomes over a lifetime. Incremental cost‐effectiveness ratios were calculated. Results: In the base‐cases analysis, universal HLA‐B*15:02 screening yielded the lowest total costs and the highest total quality‐adjusted life years (QALYs) gained. Compared with current practice, universal screening was less costly by USD100 and more effective by QALYs increase of 0.1306, while alternative prescribing resulted in 0.1383 QALYs loss at additional costs of USD332. The highest seizure remission rate (56%) was estimated for universal HLA‐B*15:02 screening vs. current practice (54%) and alternative prescribing (48%). Conclusion: Our study suggests that universal HLA‐B*15:02 screening is a cost‐effective intervention in Malaysia. With the demonstrated value of real‐world evidence in economic evaluations, more relevant standardization efforts should be emphasized to better inform decision‐making. [ABSTRACT FROM AUTHOR]